Adapt-001
Soft Tissue Sarcoma
EpicentRx, Inc.UNKNOWNPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
101 Active assets in the Soft Tissue Sarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Palbociclib Brown University | Phase 2 | BB |
Nivestim University of California, Irvine | Phase 3 | BB |
Xaliplatin OHSU Knight Cancer Institute | Phase 2 | BB |
Cyclophosphamide St. Jude Children's Research Hospital | Phase 2 | BB |
Adriamycin Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Adapt-001 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →